|
Synonyms: ABSK-043 | ABSK043 | example 110 [US11459339]
Compound class:
Synthetic organic
Comment: Lumipodlin (ABSK043) is the INN for a small-molecule programmed cell death PD-1/PD-L1 immune checkpoint, with antineoplastic potential [1]. It is designed to bind PD-1 to and block the PD-1/PD-L1 immune checkpoint, as an immuno-oncology therapeutic.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Lumipodlin (ABSK043) was progressed as a lead anti-tumour agent. It is being explored as a single agent and in combination with other chemotherapeutic drugs. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | Phase 2 Interventional | Abbisko Therapeutics Co, Ltd | ||
| NCT07014137 | A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas | Phase 2 Interventional | University Health Network, Toronto | ||